-
Under the acceleration of innovation and upgrading by domestic pharmaceutical companies, many new drugs have been introduced
Time of Update: 2022-01-09
In addition to Tasly, BeiGene also announced on December 14 that it had signed a cooperation with Wei Li Zhibo, from the latter to introduce a global research and development and production license for the LAG-3 antibody LBL-007, and Exclusive commercialization rights outside of China .
-
The financing wave of pharmaceutical companies continues. Recently, many pharmaceutical companies announced the completion of financing of hundreds of millions of yuan
Time of Update: 2022-01-09
("Omini Pharmaceutical"), an innovative pharmaceutical company focusing on the development of respiratory drug delivery technology, also announced that it has completed the D round of financing of hundreds of millions of yuan.
-
Digital reform in Zhejiang Province helps pharmaceutical farmers "sell good medicinal materials at good prices"
Time of Update: 2022-01-09
This year, in the context of the digital reform in Zhejiang Province, Pan’an County, Jinhua City, has gradually explored the construction of a high-quality and high-price system for authentic medicinal materials produced in Zhejiang Province through the construction of “Zhejiang Chinese Medicine” scene applications .
-
Crossing the 40-year-old target IL-2 to return to the hot track
Time of Update: 2022-01-09
According to publicly disclosed information: Junshi Bio will obtain an exclusive license authorized to conduct preclinical development, clinical research and commercialization of IL-2 drugs (project code: LTC002) worldwide and to use related patented technologies .
-
CSPC onslaught of innovative drugs this year, 13 category 1 new drugs were approved for clinical trials
Time of Update: 2022-01-09
Chemical sales of terminal anti-tumor drugs in public medical institutions in China (unit: ten thousand yuan) Source: Mi Nei. com, China's public medical institutions terminal competition pattern As a leading comprehensive pharmaceutical company in China , CSPC has adhered to the innovation and transformation strategy in recent years and has continued to increase R&D investment .
-
From January 1 next year, medical insurance in many places will usher in new changes!
Time of Update: 2022-01-08
It is worth noting that in addition to Beijing, the Hebei Provincial Medical Security Bureau and the Hebei Provincial Department of Human Resources and Social Security have recently formulated and issued the "Hebei Province Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2021 Edition)" (hereinafter referred to as "Drug List"), which will be officially implemented on January 1, 2022 .
-
"The "14th Five-Year Plan" Period of the Healthy Beijing Construction Plan" released the appointment rate of municipal hospitals will exceed 90%
Time of Update: 2022-01-08
The proportion of primary care visits will reach 55% In terms of balancing the distribution of high-quality health resources, the "Plan" proposes that according to the list of relief projects determined by the central government, it will coordinately promote the relief of some of the central government's tertiary hospitals outside Beijing .
-
To close in 2021, pharmaceutical companies set off a wave of listing again!
Time of Update: 2022-01-08
113 billion yuan in the past three years, of which R&D investment in 2020 will reach 581 million yuan; secondly, as of At the end of 2020, Maiwei Biosciences has a total of 429 R&D personnel, 75% of whom are R&D personnel; in addition, the company expects that three products will be approved for the market in the next two years, and the corresponding products have a broad market prospect .
-
The ophthalmology track is getting crowded day by day, and domestic and foreign pharmaceutical companies are scrambling to lay out
Time of Update: 2022-01-08
For example, on November 30, Hengrui Medicine announced the primary study endpoint of a multi-center, randomized, double-blind, salt solution parallel controlled phase III clinical trial (SHR8058-301) of SHR8058 eye drops for the treatment of dry eye related to meibomian gland dysfunction.
-
Many pharmaceutical companies such as Chutian Technology intend to be selected as the "2021 Smart Manufacturing Pilot Demonstration Factory Unveiling Unit"
Time of Update: 2022-01-08
unveiled the task name: the typical scene name of the high-end medical diagnosis and treatment equipment intelligent manufacturing demonstration factory includes direct user manufacturing; procurement strategy optimization, intelligent warehousing, real-time logistics monitoring and optimization, discrete process digital design, and production planning Optimization, advanced process control, intelligent online detection, online operation monitoring and fault diagnosis .
-
R&D is risky, and many pharmaceutical companies have recently terminated drug R&D!
Time of Update: 2022-01-08
Based on the comprehensive evaluation of the new drug's follow-up development investment and market value and other factors, it is reasonable With the allocation of R&D resources and focusing on advantageous projects in the R&D pipeline, Wanbang Pharmaceutical decided to terminate clinical trials and subsequent development of the drug .
-
Livzon Microsphere's new drug is coming and will also win 60% soaring injections
Time of Update: 2022-01-08
17 million Xiti new drug clinical approval Figure 1: Livzon’s latest clinical product information approved Source: CDE official website It is reported that Livzon’s Alanorelin Acetate Microspheres for Injection is an improved new drug that has undergone 4 years of research and development.
-
Multiple releases of documents will accelerate the introduction of new overseas drugs
Time of Update: 2022-01-08
. In this regard, the industry believes that the new regulations will encourage qualified biopharmaceutical companies to conduct applied research on a small number of drugs and medical devices that are urgently needed for clinical import, and may explore the use of relevant data for registration, so as to speed up the process of new drug launches and benefit more.
-
21 Can Jinvita be eaten for a long time?
Time of Update: 2022-01-08
Carbohydrates, protein and fat, as the three major nutrients that provide energy to the human body, have long been deeply integrated into our daily diet, but the importance of vitamins and trace elements has often been overlooked .
-
In December, multi-pharmaceutical companies were sold
Time of Update: 2022-01-08
On December 18, Kang Enbei issued an announcement on the progress of the public listing and transfer of 42% of the shares of Zhenshiming Company and the announcement of Zhenshiming Company's completion of industrial and commercial change registration .
-
The pharmaceutical machinery industry is beginning to vigorously innovate and accelerate its modernization
Time of Update: 2022-01-08
" "Bone" to realize the innovation and upgrade of domestic pharmaceutical equipment, help the modernization of the pharmaceutical manufacturing industry, and promote the high-quality development of the industry .
-
The overall trend of the pharmaceutical equipment industry in the future is relatively clear, and it will develop towards intelligence and digitalization
Time of Update: 2022-01-08
Some analysts pointed out that the overall trend of the pharmaceutical equipment industry in the future is relatively clear, and it will develop towards intelligence and digitization .
The plan has been clarified that the manufacturing industry will develop in the direction of digitization and networking in the next five years .
-
In the future, medical representatives will continue to be under pressure, where is the way out?
Time of Update: 2022-01-08
So, in the context of the continuous deepening of medical reform and the normalization of centralized procurement, how should these medical representatives find new ways in the future?
-
In 2022, the performance of the pharmaceutical machinery industry is still expected to maintain high growth
Time of Update: 2022-01-08
Analysis believes that behind the good performance of the entire pharmaceutical machinery industry and the expected continued high growth, there are several major driving factors, including the increase in demand for high-end biopharmaceutical equipment, the acceleration of import substitution, and the rapid growth of overseas business .
-
Into the field of pharmaceutical separation and purification, explore the space worth exploring
Time of Update: 2022-01-08
After years of scientific and technological development, a large number of new technologies and methods have emerged in the separation and purification of pharmaceuticals in China, such as macroporous resin adsorption, high-speed countercurrent chromatography separation technology, ultrafiltration membrane technology, etc.
